Do you want to read an article? Please log in or register.
A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
Asthma
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung Disease
Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French pharmacovigilance database
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Yavordios S, Beltramo G, Freppel R, Salinas FB, Le Beller C, Bihan K, Mouillot P, Georges M, Grandvuillemin A, Bonniaud P
doi: 10.1183/13993003.00756-2024
RECOMMENDED
Pulmonary Fibrosis
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, Foissac F, Truong NH, Benhamida M, Arnouat B, Borghese R, Chedevergne F, Couderc-Kohen L, da Silva J, Grenet D, Houdouin V, Le A, Marchal S, Deneuville E, Pouradier D, Rousseau V, Treluyer JM, Francart A, Steffann J, Reix P, Benaboud S, Mamzer MF, Ville Y, Martin C, Burgel PR, Sermet-Gaudelus I, MODUL-CF study group
doi: 10.1016/j.jcf.2025.03.009
Asthma
Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the NEWTON Study
Respir Med
Braido F, Beeh KM, Serrano CC, Dinh-Xuan AT, Tamási L, Trofor A, Ingrassia E, Piraino A, Caruso C, NEWTON study group
doi: 10.1016/j.rmed.2025.108224
Pulmonary Fibrosis
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
J Clin Med
Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M
doi: 10.3390/jcm14124335
RECOMMENDED
Lung Cancer
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wei CX, Althouse SK, Mamdani H, Hanna NH, Durm GA
doi: 10.1016/j.cllc.2024.12.007
RECOMMENDED
Lung Cancer
CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Suazo-Zepeda E, Viddeleer AR, Maas WJ, Postmus D, Heuvelmans MA, Hiltermann TJN, De Bock GH
doi: 10.1016/j.lungcan.2024.108054
Pulmonary Fibrosis
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Adv Ther
Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T
doi: 10.1007/s12325-024-03079-2
RECOMMENDED
Asthma
Real-World Phenotyping and Risk Assessment of Childhood Asthma Burden using National Registries
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Håkansson KEJ, Alabdulkarim N, Guerrero SC, Backer V, Ulrik CS, Rastogi D
doi: 10.1016/j.rmed.2024.107808
Pulmonary Fibrosis
Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost
J Cyst Fibros
Zampoli M, Verstraete J, Baird C, Biebuyck T, Calligaro G, Coetzee M, Els C, Frauendorf M, Gebers P, Morrow B, Richards D, Truter H, Hill A
doi: 10.1016/j.jcf.2025.02.002